Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Microcystic macular oedema in multiple sclerosis is associated with disease severity.
Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
EBNA1 antigen-specific CD8+ T cells in cerebrospinal fluid of patients with multiple sclerosis.
Drugs@FDA (Enter "glatiramer acetate" in search box.)
Estriol Treatment in Multiple Sclerosis: Effect on Cognition
Internal Jugular Vein Cross-Sectional Area and Cerebrospinal Fluid Pulsatility in the Aqueduct of Sylvius: A Comparative Study between Healthy Subjects and Multiple Sclerosis Patients.
Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation.
Parenteral Treatment of Multiple Sclerosis: The Advent of Monoclonal Antibodies.
Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.
Reassessing the risk of natalizumab-associated PML.
Biogen Idec and AbbVie announce positive top-line results from Phase 3 study investigating daclizumab high-yield process in multiple sclerosis
CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment.
Extended interval dosing of natalizumab in multiple sclerosis.
Glatiramer Acetate Protects Against Inflammatory Synaptopathy in Experimental Autoimmune Encephalomyelitis.
IFN-β inhibits T cells accumulation in the central nervous system by reducing the expression and activity of chemokines in experimental autoimmune encephalomyelitis.
Biologics-induced autoimmune diseases.
Ncx3 gene ablation impairs oligodendrocyte precursor response and increases susceptibility to experimental autoimmune encephalomyelitis.
Correlation of the patient's reported outcome Inflammatory-RODS with an objective metric in immune-mediated neuropathies.
Is No Evidence of Disease Activity a Realistic Goal for Patients With Multiple Sclerosis?
Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Dimethyl Fumarate Protects Brain From Damage Produced by Intracerebral Hemorrhage by Mechanism Involving Nrf2.
Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
Myelinating satellite oligodendrocytes are integrated in a glial syncytium constraining neuronal high-frequency activity.
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Extavia Prescribing Information

Pages